[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 227, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 63, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 62, "title": "Co-Founder, CEO & Director", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1009003, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 61, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 734607, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 49, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}], "auditRisk": 5, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.34, "open": 10.3, "dayLow": 10.15, "dayHigh": 11.03, "regularMarketPreviousClose": 10.34, "regularMarketOpen": 10.3, "regularMarketDayLow": 10.15, "regularMarketDayHigh": 11.03, "payoutRatio": 0.0, "beta": 2.951, "forwardPE": -3.294833, "volume": 557582, "regularMarketVolume": 557582, "averageVolume": 809752, "averageVolume10days": 1031900, "averageDailyVolume10Day": 1031900, "bid": 7.82, "ask": 13.05, "bidSize": 2, "askSize": 2, "marketCap": 619344256, "fiftyTwoWeekLow": 2.235, "fiftyTwoWeekHigh": 12.34, "allTimeHigh": 55.11, "allTimeLow": 2.235, "priceToSalesTrailing12Months": 5161.202, "fiftyDayAverage": 9.6042, "twoHundredDayAverage": 5.716075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 336544224, "profitMargins": 0.0, "floatShares": 42919868, "sharesOutstanding": 57135075, "sharesShort": 4271739, "sharesShortPriorMonth": 4488864, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0913, "heldPercentInsiders": 0.03226, "heldPercentInstitutions": 0.71998, "shortRatio": 4.96, "shortPercentOfFloat": 0.0951, "impliedSharesOutstanding": 57135075, "bookValue": 7.889, "priceToBook": 1.3740652, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -209176992, "trailingEps": -3.75, "forwardEps": -3.29, "enterpriseToRevenue": 2804.535, "enterpriseToEbitda": -1.511, "52WeekChange": 0.3569554, "SandP52WeekChange": 0.09209216, "quoteType": "EQUITY", "currentPrice": 10.84, "targetHighPrice": 45.0, "targetLowPrice": 17.0, "targetMeanPrice": 33.11111, "targetMedianPrice": 33.0, "recommendationMean": 1.54545, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 305063008, "totalCashPerShare": 5.339, "ebitda": -222704992, "totalDebt": 22263000, "quickRatio": 8.221, "currentRatio": 8.418, "totalRevenue": 120000, "debtToEquity": 6.034, "revenuePerShare": 0.002, "returnOnAssets": -0.27636, "returnOnEquity": -0.45378, "grossProfits": -177955008, "freeCashflow": -103545376, "operatingCashflow": -183496000, "revenueGrowth": 29.0, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -655.3889, "financialCurrency": "USD", "symbol": "FDMT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "marketState": "CLOSED", "cryptoTradeable": false, "regularMarketChangePercent": 4.83559, "regularMarketPrice": 10.84, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1607697000000, "postMarketChangePercent": 0.09225303, "postMarketPrice": 10.85, "postMarketChange": 0.010000229, "regularMarketChange": 0.5, "regularMarketDayRange": "10.15 - 11.03", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 809752, "fiftyTwoWeekLowChange": 8.6050005, "fiftyTwoWeekLowChangePercent": 3.8501122, "fiftyTwoWeekRange": "2.235 - 12.34", "fiftyTwoWeekHighChange": -1.5, "fiftyTwoWeekHighChangePercent": -0.12155592, "fiftyTwoWeekChangePercent": 35.69554, "earningsTimestamp": 1762781400, "earningsTimestampStart": 1762781400, "earningsTimestampEnd": 1762781400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -3.75, "epsForward": -3.29, "epsCurrentYear": -3.2586, "priceEpsCurrentYear": -3.326582, "fiftyDayAverageChange": 1.2357998, "fiftyDayAverageChangePercent": 0.12867284, "twoHundredDayAverageChange": 5.123925, "twoHundredDayAverageChangePercent": 0.89640623, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-12-11", "averageAnalystRating": "1.5 - Buy", "corporateActions": [], "postMarketTime": 1763772273, "regularMarketTime": 1763758801, "exchange": "NMS", "messageBoardId": "finmb_272879653", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "4D Molecular Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-22"}]